Study summary · research use only
A PepT1 mediated medicinal nano-system for targeted delivery of cyclosporine A to alleviate acute severe ulcerative colitis
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this study using a DSS-induced mouse model of ulcerative colitis, the authors developed a colon-specific drug delivery system, PLGA-KPV/MMT/CS nanoparticles loaded with cyclosporine A (CyA), targeting PepT1 via the lysine-proline-valine (KPV) tripeptide, with montmorillonite (MMT)/chitosan (CS) coating intended to reduce CyA leakage in the upper gastrointestinal tract and enhance adhesion to the inflamed colon. Biodistribution data showed the nanoparticles accumulated in inflamed tissues and were retained for up to 36 h. Mice treated with the CyA-loaded nanoparticles (PKMCN) showed changes in body weight, colon length, and disease activity index, and biochemistry/immunohistochemical analysis showed the PKMCN group resembled the healthy group. Nanoparticles without CyA also showed measurable effects in this model, per the authors.
Abstract
To effectively alleviate acute severe ulcerative colitis (ASUC), we developed a colon-specific delivery system-PLGA-KPV/MMT/CS multifunctional medicinal nanoparticles loaded with cyclosporine A (CyA). The lysine-proline-valine (KPV) tripeptide, which possesses anti-inflammatory properties and high affinity to peptide transporter 1 (PepT1), can target therapy-related cells (colonic epithelial cells and macrophages) via overexpression of PepT1. Montmorillonite (MMT)/chitosan (CS) coating can reduce CyA leakage in the upper gastrointestinal tract (GIT) and enhance nanoparticle adhesion to the inflamed colon. The bio-distribution demonstrated that nanoparticles can specifically accumulate in the inflamed tissues and can be retained for up to 36 h. After being treated with the CyA-PLGA-KPV/MMT/CS nanoparticles (PKMCN), the mice with DSS-induced ulcerative colitis exhibited significant improvements in body weight, colon length, and disease activity index. Moreover, biochemistry and immunohistochemical analysis showed that the PKMCN treatment group performed as well as the healthy group. Intriguingly, PKMCN without CyA also presented marked therapeutic effects. Our results suggested that PKMCN could be a promising drug delivery system for ASUC therapy by targeting inflamed cells, prolonging curative time, and mitigating colitis.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.